Dr Mila Felder Discusses Peer-to-Peer Support in Health Care Organizations
April 4th 2024Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses the impact of peer support groups within a health care organization and its patients.
Watch
Dr Jonathan Silverberg Describes AD Diagnosis, Treatment in Children vs Adults
April 2nd 2024Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences, discusses atopic dermatitis (AD) diagnosis and treatment differences in children vs adults.
Watch
Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment
April 1st 2024Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, described monitoring protocols for clinicians when using oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Watch
Dr Jeff Stark: Bimekizumab Shows Long-Term Efficacy When Used to Treat Patients With HS
April 1st 2024Despite the positive week 48 results when used to treat moderate to severe hidradenitis suppurativa (HS), Jeff Stark, MD, of Union Chimique Belge, noted that bimekizumab is still considered an investigational therapy for HS treatment as it has not yet received an FDA approval.
Watch
COA 2024: Back in Orlando With Reimbursement Challenges Topping the Agenda
April 1st 2024The annual Community Oncology Conference comes on the heels of a cyberattack that has caused significant disruption to providers, and many have sought relief from payers in areas such as prior authorization.
Read More
2024 COA Community Oncology Conference Preview With Dr Emily Touloukian
April 1st 2024With the 2024 Community Oncology Conference, from the Community Oncology Alliance (COA), set to kick off this week in Orlando, Florida, The American Journal of Managed Care® spoke with Emily Touloukian, DO, COA board member and 1 of 6 cochairs for this year’s meeting, on highlights from the packed agenda and the power of advocacy.
Watch
Patients Treated With Mirvetuximab Soravtansine vs Chemotherapy Report Better HRQOL
March 29th 2024An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.
Read More
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Dr Raj Chovatiya Provides Evidence Supporting Oral JAK Inhibitor Use to Treat AD
March 24th 2024Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, provided current clinical evidence supporting the use of oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Watch
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More
Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis
March 18th 2024Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.
Read More
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis
March 15th 2024Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, shares 16-week safety and efficacy data from the FRONTIER 2 clinical trial on JNJ-2113 for patients with moderate to severe plaque psoriasis.
Watch
Dr Krystyn Van Vliet on Using Engineered 3D Platforms to Identify Potential MS Drug Candidates
March 15th 2024Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.
Watch
Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS
March 11th 2024Jeff Stark, MD, vice president and head of medical immunology, UCB, shares phase 3 study results of bimekizumab-bkzx given for up to 48 weeks in patients with moderate to severe hidradenitis suppurativa (HS).
Watch
Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa
March 11th 2024Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Read More